Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AI-061 |
| Synonyms | |
| Therapy Description |
AI-061 is a coformulation of the anti-PDCD1 (PD-1) antibody AI-025 and the anti-CTLA4 antibody gotistobart (ONC-392), which potentially enhances antitumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AI-061 | AI 061|AI061 | CTLA4 Antibody 33 PD-L1/PD-1 antibody 133 | AI-061 is a coformulation of the anti-PDCD1 (PD-1) antibody AI-025 and the anti-CTLA4 antibody gotistobart (ONC-392), which potentially enhances antitumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05858736 | Phase I | AI-061 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009) | Active, not recruiting | AUS | 0 |